Introduction: Aortic valve stenosis is the most frequent cardiac valve pathology in the western world. In high-risk patients, conventional aortic valve replacement (C-AVR) carries high rates of morbidity and mortality. In the last few years, rapid-deployment valves (RDV) have been developed to reduce the surgical risks. In this work, we aimed to compare the mid-term outcomes of rapid-deployment AVR (RD-AVR) with those of the C-AVR in high-risk patients. Methods: This retrospective case-control study identified 23 high-risk patients who underwent RD-AVR between 12/2015 to 01/2018. The study group was compared with a control group of 46 patients who were retrospectively selected from a database of 687 C-AVR patients from 2016 to 2017 which matched with the study group for age and Euro SCORE II. Results: RD-AVR group presented more cardiovascular risk factors. Euro SCORE II was higher in the RD-AVR group (P=0.06). In the RD-AVR group, we observed significantly higher mean prosthetic size (P<0.001). In-hospital mortality was zero in RD-AVR group versus 2 deaths in C-AVR group. Hospital stay was longer in the RD-AVR group with statistical significance (P=0.03). In the group AVR with associated cardiac procedures, while comparing subgroups RD-AVR versus C-AVR, early mean gradient was lower in the first cited (P=0.02). The overall mean follow-up was 10.9 ± 4.3 months. Conclusion: The RD-AVR technique is reliable and lead to positive outcomes. This procedure provides a much larger size with certainly better flow through the aortic root. It is an alternative to C-AVR in patients recognized to be surgically fragile.
TÓM TẮT Đặt vấn đề: Đại dịch COVID-19 (coronavirus disease of 2019) do chủng vi rút Corona mới SARS-CoV-2 vẫn đang bùng phát trên toàn thế giới, gây gia tăng gánh nặng lên Hệ thống chăm sóc Y Tế các quốc gia. Chính vì vậy, việc phát triển hệ thống giúp hỗ trợ chẩn đoán và theo dõi bệnh nhân COVID-19 từ xa được xem là vấn đề cấp thiết hiện nay. Trong đó, chỉ số SpO2 có vai trò quan trọng đối với bệnh COVID-19 và được lựa chọn để theo dõi bệnh nhân tại các Cơ sở Y tế cũng như tại nhà. Nghiên cứu này được chúng tôi thực hiện với mục đích đánh giá hiệu quả ban đầu của hệ thống theo dõi SpO2từ xa trên các bệnh nhân COVID-19 mức độ nhẹ - trung bình. Đối tượng, phương pháp: Nghiên cứu cắt ngang, theo dõi dọc ngắn hạn các bệnh nhân COVID-19 mức độ nhẹ - trung bình điều trị tại Trung tâm Hồi sức Tích cực điều trị bệnh nhân COVID-19 trực thuộc Bệnh viện Trung Ương Huế tại TP. Hồ Chí Minh. Kết quả: Trong giai đoạn từ 8/2021 - 10/2021, 32 bệnh nhân COVID-19 được gắn thiết bị theo dõi chỉ số SpO2, trung bình là 34,2 ± 12,0 tuổi. Các yếu tố nguy cơ bao gồm: BMI xếp loại béo phì 25%, hút thuốc lá (18,8%), tăng huyết áp (15,6%) và đái tháo đường (12,5%). Phần lớn bệnh nhân vào viện do khó thở (71,9%) và chuyển từ tuyến dưới (62,5%). Triệu chứng lâm sàng chủ yếu là ho, hắt hơi, chảy mũi nước (40,6%), theo sau đó là giảm hoặc mất khứu giác, vị giác (25%). 81,3% có D-Dimer ≤ 500ng/mL. 62,5% bệnh nhân được phân độ COVID-19 mức trung bình. Tổng cộng 3.161 lượt đo SpO2, trong đó có 8 lượt cảnh báo SpO2 < 93%. SpO2 trung bình 98,1 ± 0,2 %. Tất cả bệnh nhân xuất viện thành công. Kết luận: Hệ thống theo dõi SpO2 từ xa bước đầu có hiệu quả giúp theo dõi các bệnh nhân COVID-19 mức độ nhẹ - trung bình. ABSTRACT INITIAL EFFECTIVENESS EVALUATION OF THE REMOTE SPO2 MONITORING SYSTEM IN PATIENTS WITH MILD - TO - MODERATE COVID-19 DISEASE Background: The COVID-19 pandemic affected by the new Coronavirus SARS-CoV-2 continues to spread globally, increasing the burden on countries’ Health Care systems. Therefore, generating a platform to help diagnose and monitor COVID-19 patients remotely is considered an essential issue today. In particular, the SpO2 index plays a vital role in COVID-19 disease and is selected to monitor patients at health facilities and homes. This study aimed to evaluate the initial effectiveness of the remote SpO2 monitoring system in patients with mild - to - moderate COVID-19 diseases. Methods: This cross - section study was conducted on mild - to - moderate COVID-19 patients treated at the COVID-19 Intensive Care Center operated by Hue Central Hospital in Ho Chi Minh City, Vietnam Results: From August 2021 to October 2021, 32 COVID-19 patients were applied with SpO2 monitoring smartwatches. The mean age was 34.2 ± 12.0. Risk factors including obesity (25%), smoking (18.8%), hypertension (15.6%), and diabetes (12.5%). Most patients were admitted to the center due to shortness of breath (71.9%) and transferred from lower - level hospitals (62.5%). The main clinical symptoms are coughing, sneezing, runny nose (40.6%), followed by a decrease or loss of smell and taste (25%). 81.3% of patients had D-Dimer ≤ 500 ng/mL. 62.5% of patients had moderate COVID-19 grades. A total of 3,161 SpO2 measurements, including 8 alarms < 93%. The average SpO2 was 98.1 ± 0.2 %. All patients were discharged successfully. Conclusion: A remote SpO2 monitoring system is considered to have preliminary effectiveness in monitoring mild - to - moderate COVID-19 patients. Keywords: COVID-19, blood oxygen saturation, smartwatch, health monitoring system.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.